MEDP
Bearish signalScored 2026-09-20 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Medpace Holdings, Inc.
- Nom
- Medpace Holdings, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $18.5B
- Employés
- 6,500
- PDG
- August James Troendle
- Site web
- https://www.medpace.com
- Marché
- CRLFTREICLRIQVWUXIF
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 226 828 titres (~141 510 433,20 $ US)
- Insiders
- Troendle August J.Kraft Robert O.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$104,730,543
Avg sell (VWAP, 90d window) $612.86 vs last close $612.33 (-0.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-30
- Liquidity
- Liquid $135,496,474/day · 20d vol
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-30 | Troendle August J. | Sell · S | 21,966 | $625.47 | $13,739,074 | Form 4 |
| 2026-09-29 | Troendle August J. | Sell · S | 26,701 | $621.02 | $16,581,855 | Form 4 |
| 2026-09-28 | Troendle August J. | Sell · S | 2,410 | $620.07 | $1,494,369 | Form 4 |
| 2026-09-25 | Troendle August J. | Sell · S | 154 | $620.60 | $95,572 | Form 4 |
| 2026-09-24 | Troendle August J. | Sell · S | 27,833 | $621.33 | $17,293,478 | Form 4 |
| 2026-09-23 | Troendle August J. | Sell · S | 16,083 | $628.64 | $10,110,417 | Form 4 |
| 2026-09-22 | Troendle August J. | Sell · S | 49,018 | $628.11 | $30,788,696 | Form 4 |
| 2026-09-21 | Troendle August J. | Sell · S | 21,883 | $623.29 | $13,639,455 | Form 4 |
| 2026-09-17 | Troendle August J. | Sell · S | 10,880 | $620.40 | $6,749,952 | Form 4 |
| 2026-09-16 | Troendle August J. | Sell · S | 8,770 | $621.29 | $5,448,713 | Form 4 |
| 2026-09-15 | Troendle August J. | Sell · S | 15,971 | $620.84 | $9,915,436 | Form 4 |
| 2026-08-27 | Troendle August J. | Sell · S | 650 | $620.27 | $403,176 | Form 4 |
| 2026-08-26 | Kraft Robert O. | Sell · S | 3,858 | $617.81 | $2,383,511 | Form 4 |
| 2026-08-26 | Troendle August J. | Sell · S | 4,000 | $620.03 | $2,480,120 | Form 4 |
| 2026-08-25 | Troendle August J. | Sell · S | 673 | $620.38 | $417,516 | Form 4 |
| 2026-08-24 | Troendle August J. | Sell · S | 1,983 | $620.23 | $1,229,916 | Form 4 |
| 2026-08-21 | Troendle August J. | Sell · S | 13,995 | $624.45 | $8,739,178 | Form 4 |
| 2026-08-20 | Brady Kevin M. | Sell · S | 3,400 | $625.24 | $2,125,816 | Form 4 |
| 2026-08-20 | Troendle August J. | Sell · S | 27,174 | $618.79 | $16,814,999 | Form 4 |
| 2026-08-19 | Carley Brian T | Sell · S | 5,000 | $608.63 | $3,043,150 | Form 4 |
| 2026-08-19 | DAVENPORT FRED B JR | Sell · S | 7,283 | $606.15 | $4,414,590 | Form 4 |
| 2026-08-19 | Troendle August J. | Sell · S | 15,609 | $606.47 | $9,466,390 | Form 4 |
| 2026-08-13 | Troendle August J. | Sell · S | 458 | $600.39 | $274,979 | Form 4 |
| 2026-08-12 | Troendle August J. | Sell · S | 11,366 | $601.53 | $6,836,990 | Form 4 |
| 2026-08-11 | McCarthy Cornelius P. III | Sell · S | 1,140 | $605.37 | $690,122 | Form 4 |
| 2026-08-11 | Troendle August J. | Sell · S | 17,610 | $605.11 | $10,655,987 | Form 4 |
| 2026-08-10 | Troendle August J. | Sell · S | 5,534 | $601.53 | $3,328,867 | Form 4 |
| 2026-08-07 | McCarthy Cornelius P. III | Sell · S | 795 | $585.07 | $465,131 | Form 4 |
| 2026-07-28 | BURWIG SUSAN E | Sell · S | 7,500 | $600.00 | $4,500,000 | Form 4 |
| 2026-07-28 | Troendle August J. | Sell · S | 3,510 | $600.01 | $2,106,035 | Form 4 |
| 2026-07-27 | Troendle August J. | Sell · S | 3,728 | $600.85 | $2,239,969 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-15 | David J. Taylor | Purchase | $1,001 - $15,000 |
| 2026-02-26 | David J. Taylor | Purchase | $1,001 - $15,000 |
| 2026-01-29 | David J. Taylor | Purchase | $1,001 - $15,000 |
| 2026-01-16 | David J. Taylor | Sale (Full) | $1,001 - $15,000 |
| 2026-01-15 | Gilbert Ray Cisneros | Sale (Full) | $15,001 - $50,000 |
| 2025-10-09 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-04 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-07-24 | Gilbert Ray Cisneros | Sale | $1,001 - $15,000 |
| 2025-07-23 | David J. Taylor | Sale (Full) | $1,001 - $15,000 |
| 2025-07-22 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-01-13 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2024-07-26 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-06-21 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-01-24 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-11-13 | Michael Guest | Purchase | $1,001 - $15,000 |
| 2022-07-22 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-10-26 | Josh S. Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-10 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2020-12-08 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-11-03 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2020-10-29 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-09-20 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
MEDP presents a deeply unfavorable event-driven profile, with a near-zero catalyst score (15) driven by heavy insider distribution (~$87M in selling, zero buys) and no identifiable near-term catalyst such as M&A…
The first sentence of the analysis written for MEDP on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Bearish signal
Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 0.74 · operating margin 21% — readings disagree
Suggested stop 590.30, nearest stored support minus 0.5 ATR(3.6% under the last close). Reward/risk to the next stored resistance is 0.12. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 30.1% | 31.1% | 27.8% | 29.6% | 28.7% | |
| Ebit Margin | 21.4% | 22.6% | 17.8% | 19.6% | 17.7% | |
| Ebitda Margin | 22.5% | 24.0% | 19.2% | 21.1% | 19.5% | |
| Operating Profit Margin | 21.1% | 21.2% | 17.9% | 19.1% | 17.4% | |
| Pretax Profit Margin | 21.4% | 22.6% | 17.8% | 19.4% | 17.7% | |
| Continuous Operations Profit Margin | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | |
| Net Profit Margin | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | |
| Bottom Line Profit Margin | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | |
| Current Ratio | 0.736 | 0.932 | 0.642 | 0.416 | 1.240 | |
| Quick Ratio | 0.736 | 0.932 | 0.642 | 0.416 | 1.240 | |
| Solvency Ratio | 0.316 | 0.340 | 0.282 | 0.277 | 0.287 | |
| Cash Ratio | 0.370 | 0.606 | 0.265 | 0.035 | 0.828 | |
| Price To Earnings Ratio | 35.911 | 25.439 | 33.318 | 28.059 | 43.012 | |
| Price To Earnings Growth Ratio | 1.818 | 0.606 | 1.547 | 0.566 | 1.768 | |
| Forward Price To Earnings Growth Ratio | 1.818 | 0.606 | 1.547 | 0.566 | 1.768 | |
| Price To Earnings Diluted Ratio | 36.757 | 26.305 | 34.519 | 29.177 | 45.247 | |
| Price To Earnings Diluted Growth Ratio | 1.752 | 0.623 | 1.571 | 0.568 | 1.791 | |
| Price To Book Ratio | 35.292 | 12.458 | 16.848 | 17.805 | 8.191 | |
| Price To Sales Ratio | 6.403 | 4.877 | 4.994 | 4.712 | 6.832 | |
| Price To Free Cash Flow Ratio | 23.760 | 17.972 | 23.737 | 19.590 | 33.205 | |
| Price To Operating Cash Flow Ratio | 22.716 | 16.893 | 21.730 | 17.728 | 29.640 | |
| Debt To Assets Ratio | 0.127 | 0.071 | 0.086 | 0.140 | 0.079 | |
| Debt To Equity Ratio | 0.546 | 0.181 | 0.254 | 0.489 | 0.137 | |
| Debt To Capital Ratio | 0.353 | 0.153 | 0.203 | 0.328 | 0.121 | |
| Long Term Debt To Capital Ratio | 0.198 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 4.303 | 2.545 | 2.964 | 3.500 | 1.742 | |
| Working Capital Turnover Ratio | -11.784 | -10.373 | -4.710 | -8.695 | 13.662 | |
| Operating Cash Flow Ratio | 0.531 | 0.551 | 0.468 | 0.483 | 0.473 | |
| Operating Cash Flow Sales Ratio | 0.282 | 0.289 | 0.230 | 0.266 | 0.231 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.956 | 0.940 | 0.915 | 0.905 | 0.893 | |
| Debt Service Coverage Ratio | 20.649 | 18.620 | 634.480 | 5.115 | 1,934.019 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 690.215 | 95.937 | 1,891.571 | |
| Short Term Operating Cash Flow Coverage Ratio | 30.730 | 26.142 | 0.000 | 7.761 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 2.847 | 4.072 | 3.049 | 2.055 | 2.011 | |
| Capital Expenditure Coverage Ratio | 22.746 | 16.658 | 11.825 | 10.522 | 9.314 | |
| Dividend Paid And Capex Coverage Ratio | 22.746 | 16.658 | 11.825 | 10.522 | 9.314 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 27.966 | 19.330 | 25.694 | 22.850 | 33.507 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 30.1% | ▼-1.1% | ▲0.6% |
| Ebit Margin | 21.4% | ▼-1.1% | ▲1.6% |
| Ebitda Margin | 22.6% | ▼-1.4% | ▲1.3% |
| Operating Profit Margin | 21.1% | ▼-0.1% | ▲1.8% |
| Pretax Profit Margin | 21.4% | ▼-1.1% | ▲1.7% |
| Continuous Operations Profit Margin | 17.8% | ▼-1.3% | ▲0.9% |
| Net Profit Margin | 17.8% | ▼-1.3% | ▲0.9% |
| Bottom Line Profit Margin | 17.8% | ▼-1.3% | ▲0.9% |
| Current Ratio | 0.737 | ▼-0.195 | ▼-0.057 |
| Quick Ratio | 0.737 | ▼-0.195 | ▼-0.057 |
| Solvency Ratio | 0.316 | ▼-0.024 | ▲0.016 |
| Cash Ratio | 0.370 | ▼-0.236 | ▼-0.051 |
| Price To Earnings Ratio | 35.911 | ▲10.472 | ▲2.763 |
| Price To Earnings Growth Ratio | 1.818 | ▲1.212 | ▲0.557 |
| Forward Price To Earnings Growth Ratio | 1.818 | ▲1.212 | ▲0.557 |
| Price To Earnings Diluted Ratio | 36.757 | ▲10.452 | ▲2.356 |
| Price To Earnings Diluted Growth Ratio | 1.752 | ▲1.129 | ▲0.491 |
| Price To Book Ratio | 35.292 | ▲22.833 | ▲17.173 |
| Price To Sales Ratio | 6.403 | ▲1.527 | ▲0.840 |
| Price To Free Cash Flow Ratio | 23.760 | ▲5.788 | ▲0.107 |
| Price To Operating Cash Flow Ratio | 22.716 | ▲5.822 | ▲0.974 |
| Debt To Assets Ratio | 0.127 | ▲0.056 | ▲0.026 |
| Debt To Equity Ratio | 0.546 | ▲0.364 | ▲0.224 |
| Debt To Capital Ratio | 0.353 | ▲0.200 | ▲0.121 |
| Long Term Debt To Capital Ratio | 0.198 | ▲0.198 | ▲0.159 |
| Financial Leverage Ratio | 4.303 | ▲1.758 | ▲1.292 |
| Working Capital Turnover Ratio | -11.784 | ▼-1.410 | ▼-7.404 |
| Operating Cash Flow Ratio | 0.531 | ▼-0.020 | ▲0.030 |
| Operating Cash Flow Sales Ratio | 0.282 | ▼-0.007 | ▲0.023 |
| Free Cash Flow Operating Cash Flow Ratio | 0.956 | ▲0.016 | ▲0.034 |
| Debt Service Coverage Ratio | 20.649 | ▲2.029 | ▼-501.927 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▼-535.545 |
| Short Term Operating Cash Flow Coverage Ratio | 30.730 | ▲4.589 | ▲17.804 |
| Operating Cash Flow Coverage Ratio | 2.847 | ▼-1.224 | ▲0.041 |
| Capital Expenditure Coverage Ratio | 22.746 | ▲6.088 | ▲8.533 |
| Dividend Paid And Capex Coverage Ratio | 22.746 | ▲6.088 | ▲8.533 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 27.966 | ▲8.636 | ▲2.097 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $16.20B | $10.28B | $9.42B | $6.88B | $7.81B | |
| Enterprise value | $15.95B | $9.76B | $9.31B | $7.04B | $7.47B | |
| EV / Sales | 6.31x | 4.63x | 4.94x | 4.82x | 6.54x | |
| EV / Op. cash flow | 22.37x | 16.04x | 21.49x | 18.14x | 28.39x | |
| EV / Free cash flow | 23.40x | 17.06x | 23.48x | 20.05x | 31.80x | |
| EV / EBITDA | 27.97x | 19.33x | 25.69x | 22.85x | 33.51x | |
| Net debt / EBITDA | -0.43x | -1.03x | -0.28x | 0.52x | -1.48x | |
| Current ratio | 0.74x | 0.93x | 0.64x | 0.42x | 1.24x | |
| Income quality | 1.58x | 1.51x | 1.53x | 1.58x | 1.45x | |
| Graham number | $75 | $89 | $61 | $45 | $55 | |
| Graham net-net | -$25 | -$12 | -$20 | -$23 | -$3 | |
| Tax burden | 83.2% | 85.0% | 84.2% | 86.7% | 90.1% | |
| Interest burden | 100.0% | 100.0% | 99.9% | 99.0% | 99.9% | |
| Working capital | -$354.1M | -$75.3M | -$331.3M | -$469.5M | $133.7M | |
| Invested capital | $590.6M | $873.7M | $632.3M | $479.8M | $1.06B | |
| Return on assets | 22.8% | 19.2% | 17.1% | 18.1% | 11.0% | |
| Operating ROA | 26.2% | 23.8% | 22.4% | 18.5% | 13.0% | |
| Return on tangible assets | 35.3% | 28.8% | 29.5% | 37.6% | 19.0% | |
| Return on equity | 98.3% | 49.0% | 50.6% | 63.5% | 19.1% | |
| Return on invested capital | 67.9% | 37.2% | 38.8% | 40.4% | 16.2% | |
| Return on capital employed | 84.7% | 44.9% | 46.0% | 50.8% | 18.0% | |
| Earnings yield | 2.8% | 3.9% | 3.0% | 3.6% | 2.3% | |
| Free cash flow yield | 4.2% | 5.6% | 4.2% | 5.1% | 3.0% | |
| Capex / Op. cash flow | 4.4% | 6.0% | 8.5% | 9.5% | 10.7% | |
| Capex / Depreciation | 115.4% | 124.9% | 139.2% | 165.1% | 133.9% | |
| Capex / Sales | 1.2% | 1.7% | 1.9% | 2.5% | 2.5% | |
| SG&A / Sales | 7.8% | 8.5% | 8.6% | 9.0% | 9.5% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.4% | 1.2% | 1.1% | 1.5% | 1.3% | |
| Intangibles / Total assets | 35.2% | 33.2% | 42.1% | 51.8% | 42.4% | |
| Days sales outstanding | 58d | 51d | 58d | 63d | 60d | |
| Days payables outstanding | 6d | 8d | 9d | 12d | 12d | |
| Operating cycle | 58d | 51d | 58d | 63d | 60d | |
| Cash conversion cycle | 52d | 43d | 49d | 52d | 48d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+57.5%EV / Sales ▲+36.2%EV / EBITDA ▲+44.7%EV / Op. cash flow ▲+6.331Earnings yield ▼-0.011Graham number ▼-13.699
Profitability
Return on equity ▲+0.493Return on assets ▲+0.036Return on invested capital ▲+0.307Return on capital employed ▲+0.398Operating ROA ▲+0.025Income quality ▲+0.075Tax burden ▼-0.018
Efficiency
Days sales outstanding ▲+6.699Days payables outstanding ▼-2.368Operating cycle ▲+6.699Cash conversion cycle ▲+9.067Capex / Sales ▼-0.005R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.195Net debt / EBITDA ▲+0.597Working capital ▼-278800000.000Invested capital ▼-283140000.000Intangibles / Total assets ▲+0.021
Change over 5 years
Valuation
Market cap ▲+107.6%EV / Sales ▼-3.6%EV / EBITDA ▼-16.5%EV / Op. cash flow ▼-6.015Earnings yield ▲+0.005Graham number ▲+19.772
Profitability
Return on equity ▲+0.792Return on assets ▲+0.119Return on invested capital ▲+0.517Return on capital employed ▲+0.667Operating ROA ▲+0.132Income quality ▲+0.133Tax burden ▼-0.069
Efficiency
Days sales outstanding ▼-1.565Days payables outstanding ▼-5.706Operating cycle ▼-1.565Cash conversion cycle ▲+4.142Capex / Sales ▼-0.012R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.503Net debt / EBITDA ▲+1.049Working capital ▼-487819000.000Invested capital ▼-469600000.000Intangibles / Total assets ▼-0.072
Employee count
Peer market caps
Recent news
- 2026-10-05 Medpace Holdings, Inc. $MEDP Stock Holdings Decreased by Argent Capital Management LLC Argent Capital Management LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ: MEDP) by 5.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 56,996 shares of the company''s stock after selling 3,218 shares during the period. Medpace accounts for approximately 0.3% of Argent Capital
- 2026-09-29 Medpace (MEDP) Rises As Market Takes a Dip: Key Facts In the closing of the recent trading day, Medpace (MEDP) stood at $622.11, denoting a +1% move from the preceding trading day.
- 2026-09-28 CON or MEDP: Which Is the Better Value Stock Right Now? Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
- 2026-09-28 Envestnet Asset Management Inc. Cuts Position in Medpace Holdings, Inc. $MEDP Envestnet Asset Management Inc. lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 30.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,802 shares of the company''s stock after selling 40,222 shares during the period. Envestnet Asset Management
- 2026-09-24 Medpace (NASDAQ:MEDP) CEO August Troendle Sells 21,883 Shares Medpace Holdings, Inc. (NASDAQ: MEDP - Get Free Report) CEO August Troendle sold 21,883 shares of the business''s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $623.29, for a total value of $13,639,455.07. Following the completion of the transaction, the chief executive officer directly owned 482,390 shares
- 2026-09-24 Medpace (NASDAQ:MEDP) CEO August Troendle Sells 49,018 Shares Medpace Holdings, Inc. (NASDAQ: MEDP - Get Free Report) CEO August Troendle sold 49,018 shares of Medpace stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the completion of the sale, the chief executive officer owned 433,372 shares in the
- 2026-09-24 State Street Corp Buys 28,666 Shares of Medpace Holdings, Inc. $MEDP State Street Corp increased its stake in Medpace Holdings, Inc. (NASDAQ: MEDP) by 4.2% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 710,895 shares of the company''s stock after acquiring an additional 28,666 shares during the period. State Street Corp owned about 2.55% of
- 2026-09-22 Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026 CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended yo.
- 2026-09-21 Medpace (MEDP) Outperforms Broader Market: What You Need to Know Medpace (MEDP) concluded the recent trading session at $624.2, signifying a +1.94% move from its prior day''s close.
- 2026-09-18 Medpace Holdings, Inc. $MEDP Stock Position Decreased by Integrated Wealth Concepts LLC Integrated Wealth Concepts LLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 29.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,287 shares of the company''s stock after selling 936 shares during the quarter.